Document resource
Introduction The CORTRAK 2 Enteral Access System (EAS) enables real-time electromagnetic guidance for bedside Naso jejunal tube (NJT) placement, reducing reliance on endoscopy and radiology. NICE endorses it as a safe alternative to endoscopic placement.Methods A retrospective review of 128 NJT placements (May 2024–May 2025) was conducted. Data were collected via electronic referral systems and stratified by technique (Cortrak2 vs. OGD-guided), location (inpatient/outpatient), and outcome. Inclusion criteria encompassed adults with normal upper GI anatomy requiring post-pyloric feeding.Results During a year of evaluation period (May 2024–May 2025), a total of 128 Naso jejunal tube (NJT) placements were performed. Of these, 81 procedures (63.3%) were carried out using endoscopic guidance (OGD + NJ), while 47 procedures (36.7%) utilised the Cortrak2 Enteral Access System (EAS).Among the Cortrak2 group, 43 placements (91.5%) were successful, with 4 cases (8.5%) requiring subsequent endoscopic insertion. In contrast, all 81 endoscopic placements (100%) were successful. Stratified by location, 106 procedures were performed in inpatients and 22 in outpatients, with Cortrak2 accounting for 28 inpatient and 17 outpatient cases.Notably, 20 patients (46.5% of the Cortrak2 cohort) achieved sameday discharge; 19 patients (53.5%) were not discharged the same day due to other ongoing medical needs unrelated to NJT placement, confirming that delays were not attributable to the Cortrak2 procedure itself. Median referraltoprocedure time was significantly shorter with Cortrak2 at 26.4 hours (1.1 days) compared to 45.6 hours (1.9 days) for endoscopic placement.Procedure duration was also reduced by 50%, with Cortrak2 requiring median ~12 minutes versus approximately median 30 minutes for endoscopic insertion.Unlike endoscopic NJT placement, which universally required sedation, Cortrak2-guided insertion was performed safely at the bedside without sedation, reducing procedural risk and enhancing patient safetyThese efficiencies translated into substantial savings, with £34,840 realised in one year and a potential of £66,970 if adopted more widely.Conclusion Cortrak2-guided Naso jejunal tube placement proved safe, efficient, and cost-effective. Compared to endoscopic insertion, Cortrak2 halved referral-to-procedure time ( 26.4 vs 45.6 hours) and procedure duration (~12 vs 30 minutes), while avoiding the need for sedation. Nearly half of patients achieved same-day discharge, with others remaining in hospital due to unrelated medical needs. Cortrak2 offers a faster, safer, and more economical pathway for post-pyloric feeding and should be considered first-line in appropriate patients.Cortrak2 EAS offers a safe, efficient, and cost-effective alternative to endoscopic NJT placement. It significantly reduces procedure time, inpatient stay, and financial burden. Wider adoption and staff training could enhance service delivery and patient outcomes.